Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
B1CMneX9EySnkaM3
